Sumitomo Dainippon Pharma Stock Revenue

DNPUFDelisted Stock  USD 4.37  0.00  0.00%   
Sumitomo Dainippon Pharma fundamentals help investors to digest information that contributes to Sumitomo Dainippon's financial success or failures. It also enables traders to predict the movement of Sumitomo Pink Sheet. The fundamental analysis module provides a way to measure Sumitomo Dainippon's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sumitomo Dainippon pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sumitomo Dainippon Pharma Company Revenue Analysis

Sumitomo Dainippon's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Current Sumitomo Dainippon Revenue

    
  560.03 B  
Most of Sumitomo Dainippon's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sumitomo Dainippon Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, Sumitomo Dainippon Pharma reported 560.03 B of revenue. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is significantly lower than that of the firm.

Sumitomo Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sumitomo Dainippon's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sumitomo Dainippon could also be used in its relative valuation, which is a method of valuing Sumitomo Dainippon by comparing valuation metrics of similar companies.
Sumitomo Dainippon is currently under evaluation in revenue category among its peers.

Sumitomo Fundamentals

About Sumitomo Dainippon Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sumitomo Dainippon Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sumitomo Dainippon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sumitomo Dainippon Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Consideration for investing in Sumitomo Pink Sheet

If you are still planning to invest in Sumitomo Dainippon Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sumitomo Dainippon's history and understand the potential risks before investing.
Global Correlations
Find global opportunities by holding instruments from different markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Fundamental Analysis
View fundamental data based on most recent published financial statements
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios